{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:29:29Z","timestamp":1784194169221,"version":"3.55.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"PaxVax for conducting the reformulated CVD 103-HgR trials","award":["NCT1585181"],"award-info":[{"award-number":["NCT1585181"]}]},{"name":"PaxVax for conducting the reformulated CVD 103-HgR trials","award":["NCT01895855"],"award-info":[{"award-number":["NCT01895855"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.2217\/fmb.15.51","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T08:06:32Z","timestamp":1438329992000},"page":"1271-1281","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Evidence for CVD 103-HgR as an Effective Single-Dose Oral Cholera Vaccine"],"prefix":"10.1080","volume":"10","author":[{"given":"Sarah S","family":"Jackson","sequence":"first","affiliation":[{"name":"Department of Epidemiology & Public Health, University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbur H","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, 685 W. Baltimore Street, Suite 480, Baltimore, MD21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"issue":"31","key":"e_1_3_3_3_1","first-page":"345","article-title":"2013","volume":"89","author":"Cholera","year":"2014","unstructured":"Cholera 2013 . Wkly Epidemiol. Rec.89 ( 31 ), 345 \u2013 355 ( 2014 ).","journal-title":"Wkly Epidemiol. Rec."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.093427"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.09.9"},{"issue":"13","key":"e_1_3_3_6_1","first-page":"117","volume":"85","author":"Cholera vaccines: WHO position paper","year":"2010","unstructured":"Cholera vaccines: WHO position paper . Wkly Epidemiol. Rec.85 ( 13 ), 117 \u2013 128 ( 2010 ).","journal-title":"Wkly Epidemiol. Rec."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90019-T"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2051013614537819"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit009"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/315462"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90755-2"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002828"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312680"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.108"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.11.049"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.5.1029"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61297-6"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70273-1"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60436-X"},{"key":"e_1_3_3_20_1","volume-title":"ASTMH 63rd Annual Meeting.","author":"Chen W","year":"2014","unstructured":"Chen W , CohenM , KirkpatrickBet al. Single-dose live attenuated oral cholera vaccine (CVD 103-HgR) protects against cholera at 10 days following vaccination: results of a Vibrio cholerae O1 El Tor Inaba challenge study . Presented at : ASTMH 63rd Annual Meeting.LA, USA , November 2014 ."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00601-13"},{"key":"e_1_3_3_22_1","unstructured":"ClinicalTrials.gov identifier: NCT02094586 . www.clinicaltrials.gov ."},{"key":"e_1_3_3_23_1","unstructured":"PaxVax . PaxVax announces primary endpoints met in Phase 3 Cholera Vaccine Trial . Press Release . http:\/\/www.paxvax.com ."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-2452(96)85758-7"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.12.033"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199907000-00011"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.4.837"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.10.4430-4432.1992"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.12.6341-6345.1999"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(90)90012-B"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.9.3916-3917.1992"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.4.1336-1339.1995"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.4.1454-1457.1996"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.57.11.3261-3264.1989"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.6.1042"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92231-4"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.5.1169"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.9.3994-3997.1993"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.2.707-709.1995"},{"issue":"1","key":"e_1_3_3_40_1","first-page":"63","article-title":"A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali","volume":"76","author":"Perry RT","year":"1998","unstructured":"Perry RT , PloweCV , KoumareBet al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali . Bull. World Health Organ.76 ( 1 ), 63 \u2013 71 ( 1998 ).","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.070"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90120-1"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.2.729-733.1993"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1086\/652404"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1993.tb06355.x"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00218-P"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.4.1480-1483.1994"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2008.02051.x"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biosystems.2012.05.002"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199510000-00019"},{"key":"e_1_3_3_51_1","unstructured":"UN Joint Programme on HIV\/AIDS (UNAIDS): The Gap Report: 2014 . ISBN 978-92-9253-062-4 ( 2014 ). http:\/\/www.unaids.org ."},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00006-2"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66550-6"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040336"},{"key":"e_1_3_3_55_1","article-title":"PaxVax will seek FDA approval of single-dose cholera vaccine","author":"Mackinder M","year":"2014","unstructured":"Mackinder M . PaxVax will seek FDA approval of single-dose cholera vaccine . Vaccine News Daily ( 8 December 2014 ). http:\/\/vaccinenewsdaily.com .","journal-title":"Vaccine News Daily"},{"key":"e_1_3_3_56_1","unstructured":"ClinicalTrials.gov identifier: NCT02100631 . www.clinicaltrials.gov ."},{"key":"e_1_3_3_57_1","unstructured":"ClinicalTrials.gov identifier: NCT02145377 . www.clinicaltrials.gov ."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/FMB.15.51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:48Z","timestamp":1719124728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/FMB.15.51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.2217\/FMB.15.51"],"URL":"https:\/\/doi.org\/10.2217\/fmb.15.51","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-07-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}